The merger between Caprion and HistoGeneX allows us to offer a full suite of histopathology services. As a leader in the field of histopathology, counting on an experienced team of pathologists, HistoGeneX has been involved in many clinical studies and developed several assays.
HistoGeneX’s expertise in the field:
Services from both histopathology and genomic platforms can be coordinated to provide integrated solutions and our scientific team can customize assays based on your specific needs.
With proficiency in multiple staining platforms, the HistoGeneX team can support large scale studies from discovery to late phase clinical trials and maintain a quick turnaround time aligned with clinical needs. Well established sample processing protocols, including the possibility of sample rescue for poor FFPE samples, ensures quality data.
Leveraging HistoGeneX strong expertise in immunohistochemistry (IHC) and immunofluorescence (IF) assays, get a detailed picture of the abundance, distribution, and localization of antigens of interests in tissues or cells. IHC assays can be performed with both chromogenic and fluorescent labeling methods and all major platforms are available including the ones from Ventana Medical Systems, Dako, and Leica Biosystems BOND.
Highly multiplex immunofluorescence imaging can bring valuable and extensive data from scarce clinical samples. Using multiplex or single assays, our team can look at various CD markers, T-cell activation and exhaustion markers, antigen presentation and immune cell infiltration markers, and characterize the tumor microenvironment (TME).
This molecular analysis method, which provides the precise localization and quantification of nucleic acids such as DNA, mRNA, and microRNA, is a powerful tool in oncology for the analysis of genetic abnormalities. HistoGeneX offers all methods of probe detection: fluorescence (FISH), chromogenic (CISH), and silver (SISH) in situ hybridization.
Using single ISH, our team can screen for the expression of a specific gene. We also harnessed to power of dual ISH, an important tool to assess gene inversion, translocation, or duplication in cancer sample analysis.
This simple yet essential technique provides a broad view of various cellular features. Our pathologists commonly use it to investigate the presence of tumor infiltrating lymphocytes (TILs) and stromal TILs in clinical samples.
HistoGeneX’s Hematoxylin and Eosin (H&E) staining services provide a reliable view of cellular and tissue structures in formalin-fixed, paraffin-embedded, or fresh frozen tissue. For consistent results, all our H&E staining procedures are monitored by our certified pathologists.
Our team of in-house pathologists is composed of experts who received extensive internal and external training. Their expertise spans different fields including angiogenesis, tumor signaling, proliferation, and apoptosis, and they each have their own tissue sub-specialty.
They have access to the latest imaging technologies including 3DHISTECH’s Panoramic 250 and 1000, the Ventana DP 200, Zeiss’ Axio Scan.Z1, RareCyte’s CyteFinder® HT, BioView’s Duet 3 and Allegro Plus, as well as key image analysis software: Visiopharm and HALO®.
In addition to ensuring our certified pathologists have access to the best tools, we use Pathomation’s Global Connectivity platform to enable digital image viewing, which leads to better scoring.
As we believe teamwork and education is key in accelerating research, we offer a pathology training program to our clients called:
Circulating tumor cells (CTCs) provide a dynamic view of cancer progression and can be detected in peripheral blood. Our well-defined blood processing workflow in combination with the RareCyte® platforms (CytePicker® and CyteFinder®) allow us to easily identify and phenotype these cells. In addition, the technology allows us to select CTCs and perform a genomic analysis at the single cell level.
Using this technology, we offer the possibility to perform both fluorescent staining and genomic analysis on single cells. The reproducible automated staining and analysing process enables the use of this platform in large scale clinical trials.